Screener
Neurocrine Biosciences NBIX Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except weighted average data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Sublease income | (0.9) | (0.9) |
| Net operating lease cost | $14.5 | $15.6 |
| Cash paid for amounts included in the measurement of operating lease liabilities | $12.7 | $9.3 |
| March 31, | ||
| 2026 | 2025 | |
| Weighted average remaining lease term | 9.7 years | 10.6 years |
| Weighted average discount rate | 4.9% | 4.9% |
| Restricted cash related to leases | $7.8 | $7.8 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's operating lease ROU assets?
- Neurocrine Biosciences (NBIX) reported operating lease ROU assets of 4.9% in Q1 2026.
- How has Neurocrine Biosciences's operating lease ROU assets changed year-over-year?
- Neurocrine Biosciences's operating lease ROU assets decreased by 0.0% year-over-year, from 4.9% to 4.9%.
- What is the long-term trend for Neurocrine Biosciences's operating lease ROU assets?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's operating lease ROU assets has grown at a 40.6% compound annual growth rate (CAGR), from 8,280,000,000% to 45,540,000,000%.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about Neurocrine Biosciences's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude